Sensitive, specific radioimmunoassay for quantifying pergolide in plasma.
Pergolide, a synthetic ergoline with potent dopaminergic activity, is used to treat Parkinson disease. The low plasma concentrations of pergolide achieved during therapy complicate the development of a method for its analysis. Because radioimmunoassay successfully measures other structurally related ergolines in physiological fluids, we undertook the development of a radioimmunoassay of pergolide. The detection limit of the radioimmunoassay is 21 ng/L with an optimal working range from 100 to 1000 ng/L. We maximized assay specificity by using a monoclonal antibody that displayed low cross-reactivity with pergolide sulfoxide, a major metabolite found in animals. The radioimmunoassay has performed acceptably for > 2 years during toxicology studies with rats and rhesus monkeys and in clinical studies involving patients with Parkinson disease. We consider the radioimmunoassay a valid method for quantifying therapeutic concentrations of pergolide in plasma.
Bowsher
R R
RR
Department of Drug Disposition & Bioanalytical Research, Eli Lilly and Co., Wishard Memorial Hospital, Indianapolis, IN 46202.
Apathy
J M
JM
Compton
J A
JA
Wolen
R L
RL
Carlson
K H
KH
DeSante
K A
KA
D000818:Animals; D000911:Antibodies, Monoclonal; D006801:Humans; D007700:Kinetics; D008253:Macaca mulatta; D008832:Microchemistry; D010300:Parkinson Disease / Q000097:blood*; D010479:Pergolide / Q000097:blood* / Q000493:pharmacokinetics; D011863:Radioimmunoassay / Q000379:methods* / Q000592:standards / Q000706:statistics & numerical data
D000911:Antibodies, Monoclonal; D010479:Pergolide